Search Results

You are looking at 91 - 100 of 466 items for :

  • Refine by Access: All x
Clear All
Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda L. Telli, John H. Ward, Rashmi Kumar, and Dorothy A. Shead

, determination of tumor estrogen receptor (ER) status, and MRI as indicated. For pathology reporting, the NCCN panel endorses the College of American Pathologists' protocol for both invasive and noninvasive carcinomas of the breast. 1 The NCCN Guidelines Panel

Full access

Mark D. Tyson and Sam S. Chang

annually up to 5 years. 2 If the patient underwent a partial nephrectomy, a baseline abdominal CT, MRI, or ultrasound is recommended within 3 to 12 months of surgery, then annually for 3 years if the baseline scan is negative. Recognizing that the risk of

Full access

Anne M. Covey

≥10 mm on ultrasound and capsular retraction or vascular invasion, further workup with CT or MRI would be required ( Figure 1 ). In the United States, Dr. Covey noted that CT and MRI seem to be used more often than ultrasound for detecting HCC. In

Full access

days 16 through 20. TAS-102 will be self-administered (in tablet form) by the study participant and documented in a provided drug diary. Response assessment via CT imaging (or MRI) will be obtained every 8 weeks. Treatment will continue until disease

Full access

Dong-Xu Qiu, Jian Li, Jin-Wei Zhang, Min-Feng Chen, Xiao-Mei Gao, Yong-Xiang Tang, Ye Zhang, Xiao-Ping Yi, Hong-ling Yin, Yu Gan, Gui-Lin Wang, Xiong-Bing Zu, Shuo Hu, and Yi Cai

INTRODUCTION AND OBJECTIVE : Growing evidence proved the efficacy of multiparametric MRI (mpMRI) and prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT)-guided targeted biopsy (TB) in prostate

Full access

Anastasia Tararykova, Alexander Fedenko, and Elmar Musaev

observed 40 advanced or unresectable GCT cases from 2005 till 2020 in N.N. Blokhin NMRCO. Patients underwent CT/MRI every 3 months during the first three years and then once every six months. Patient received subcutaneous denosumab (Db) 120 mg every 4 weeks

Full access

Steven J. Schuetz, Claudia B. Soliz P., Maribel Marmol C., Marco A. Vasquez V., and Robert W. Carlson

basic, core and enhanced resource levels will utilize rigid proctoscopy and pelvic CT due to inaccessibility of MRI and endorectal ultrasound, with abdominal ultrasound and chest radiographs to evaluate metastatic disease at basic and core levels

Full access

6 and days 16 through 20. TAS-102 will be self-administered (in tablet form) by the study participant and documented in a provided drug diary. Response assessment via CT imaging (or MRI) will be obtained every 8 weeks. Treatment will continue until

Full access

Peter R. Carroll, J. Kellogg Parsons, Gerald Andriole, Robert R. Bahnson, Daniel A. Barocas, Erik P. Castle, William J. Catalona, Douglas M. Dahl, John W. Davis, Jonathan I. Epstein, Ruth B. Etzioni, Thomas Farrington, George P. Hemstreet III, Mark H. Kawachi, Paul H. Lange, Kevin R. Loughlin, William Lowrance, Paul Maroni, James Mohler, Todd M. Morgan, Robert B. Nadler, Michael Poch, Chuck Scales, Terrence M. Shaneyfelt, Marc C. Smaldone, Geoffrey Sonn, Preston Sprenke, Andrew J. Vickers, Robert Wake, Dorothy A. Shead, and Deborah Freedman-Cass

the American College of Radiology gives recommendations for high-quality MRI in prostate cancer care, including recommendations related to the use of MRI to direct targeted biopsies. 106 In addition, the European Society of Urogenital Radiology

Full access

Kaylene Ready and Banu Arun

, proven screening and risk reduction modalities are available. For example, a woman carrying a BRCA1 or BRCA2 mutation can be offered the following risk management options: semiannual breast cancer screening using both mammogram and breast MRI 3